Skip to main content

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Active, not recruiting · Phase 3 · NCT04224493

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

At a glance

Research payments reported, 2025
$2.9M
U.S. investigators named
58
Sites paid
52
Planned or actual enrollment
599

About the trial

Sponsor
Epizyme, Inc.
Tested
Tazemetostat (drug), Tazemetostat (drug), Placebo oral tablet (drug), Lenalidomide (combination_product), Rituximab (combination_product)
Dates
Started 2020-06-11; completion 2029-03-01
Results posted
Not yet

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial studied the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 were designed to evaluate and compare how long participants live without their disease getting …

From ClinicalTrials.gov, last updated 2026-10-05. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Epizyme, Inc. reported $2.9M in research payments for this study in 2025 (1,967 payments).

Products named: Tazverik

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • US Oncology Research LLC $692,524
  • Moffitt Cancer Center $449,766
  • Memorial Sloan Kettering Cancer Center $237,910
  • Sarah Cannon Research Institute $225,990
  • University of Utah Hospital and Clinics, UT $203,968
  • Gabrail Cancer and Research Center $131,049
  • Regional Cancer Care Associates $101,932
  • University of Chicago Medical Center $96,659
  • Mayo Clinic $91,784
  • Ronald Reagan UCLA Medical Center, CA $72,650
  • Unehealth $68,848
  • Weill Cornell Medical College $55,110
  • University of Nebraska Medical Center $47,493
  • Utah Cancer Specialists $43,680
  • The Trustees of Columbia University in The City of New York $35,020
  • Ocala Oncology Center $32,649
  • New Mexico Cancer Care Alliance $31,975
  • West Virginia University School of Medicine $31,390
  • Allegheny Singer Research Institute $25,966
  • UCSF Langley Porter Psychiatric Hospital and Clinics, CA $23,622
  • Moore Regional Hospital - Hospital $23,255
  • Cancer Specialists of North Florida Southside $22,406
  • Cancer Specialists of North Florida $18,458
  • Regional Cancer Care Associates Freehold $18,254
  • Carolinas Medical Center-Northeast, NC $17,279
  • Ut MD Anderson Cancer Center $16,908
  • University of Michigan Health System, MI $16,570
  • Tennessee Oncology, PLLC $13,398
  • Siouxland Regional Cancer Center $12,391
  • Moore Regional Hospital Chs $11,776
  • Cedars Sinai the Angeles Clinic and Research Institute $11,216
  • Cancer Specialists LLC $10,480
  • The University of Texas Health Science Center at San Antonio $9,585
  • $7,790
  • American Institute of Research $6,990
  • Biomedical Research Alliance of New York $6,430
  • Texas Oncology Kingwood North $5,500
  • University of Texas Health Science Center at Tyler, TX $5,491
  • Mohtaseb Cancer Center and Blood Disorders $2,901
  • Millennium Physicians Association, PLLC $1,750
  • Highland Medical, PC $1,456
  • Trinity Health Imaging Ann Arbor Hospital $1,000
  • Weill Cornell Medicine Gale and Ira Drukier Institute for Childrens Health $531
  • Helios Clinical Research $250
  • Florida Cancer Specialists and Research Institute $234
  • University of California San Francisco School of Medicine $156
  • UCSF Fresno Medical Center $156
  • Regional Medical Oncology Center $141
  • Sheboygan Cancer & Blood Specialist $141
  • Lumi Research $117
  • Regional Cancer Care Associates Little Silver $117
  • Astera Cancer Care $78

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.